Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging

Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01780766

Enrollment

100

Registered

2013-01-31

Start date

2008-09-30

Completion date

2014-09-30

Last updated

2013-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Whole body MRI, Multiple myeloma, Diffusion Weighted MRI, Whole body scan

Brief summary

Whole body MRI with diffusion weighted imaging is a useful imaging tool * staging and diagnosis * therapy monitoring All patients will be scanned before and during treatment. The findings on diffusion weighted imaging will be correlated to the golden standard (computer tomography and MRI (T1 and STIR)).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with clinical and laboratory findings, highly suggestive for multiple myeloma.

Exclusion criteria

* All patients who are not allowed to be scanned on MRI (Pacemaker, implants ed.)

Design outcomes

Primary

Measure	Time frame	Description
Validation	2 years	Validation of whole body MRI diffusion-weighted imaging in multiple myeloma at 3 Tesla MRI: correlation of the new MRI imaging technique (diffusion weighted imaging)to standard validated imaging technique (Computer Tomography and Magnetic Resonance Imaging)

Secondary

Measure	Time frame	Description
Therapy assessment	4 years	Whole body MRI with Diffusion weighted imaging is useful for treatment monitoring in multiple myeloma patients during and after therapy. Measurement of apparent diffusion coefficient (ADC) and comparison of ADC before, during and after therapy. Correlation of ADC with clinical findings and standard MRI findings.

Other

Measure	Time frame	Description
outcome	5 years	correlation between early treatment response and outcome of the patient by measuring apparent diffusion coefficient

Countries

Belgium

Contacts

Primary ContactSteven Pans, MD

steven.pans@uzleuven.be3216340505

Outcome results